FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. Drug Supply Chain
Audience: Consumers
April 14, 2025 -- FDA was notified by Novo Nordisk on April 3, 2025, that several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg were in the U.S. drug supply chain. The counterfeit products were distributed outside the Novo Nordisk authorized supply chain in the U.S. FDA seized the identified counterfeit products on April 9, 2025.
The agency advises patients, wholesalers, retail pharmacies and health care professionals to check the Ozempic products they have received and not use, distribute or sell products labeled with lot number PAR0362 and serial number starting with the first eight digits 51746517 as pictured below.
FDA is aware of six adverse event reports associated with this lot, however none of them appear to be associated with the counterfeit product. All six adverse events were reported by Novo Nordisk.
FDA and Novo Nordisk are testing the seized products and do not yet have information about the identity, quality or safety of these drugs. FDA’s investigation is ongoing, and the agency is working to protect the U.S. drug supply. Visit Novo Nordisk’s announcement for more information.
Source: FDA
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.